• AMILI

  Participated · Series A · Jun 2022

  AMILI is a Singapore precision gut microbiome company founded in 2019 that builds a multi-ethnic repository of microbiome data and samples, including the only existing microbiome bank in Southeast Asia. Its core products include diagnostics, predictive algorithms and microbiome-modifying interventions powered by its proprietary analytics engine, AMILI Prime. The company licenses its database to academic institutions, biotech firms and food manufacturers to identify biomarkers and inform product formulation. AMILI also provides faecal microbiota transplants and has launched a consumer health brand, BIO & ME, offering probiotics and diagnostic tests based on its database, with planned rollouts in Southeast Asia and Hong Kong later this year. It focuses clinical research on health and wellness, oncology, and response to microbiome-based therapeutics, having conducted over 20 research studies valued at over $40 million. The company intends to use new funding to expand in Southeast Asia and the rest of Asia, pursue additional research partnerships, and further develop AMILI Prime.

• One Health Group

  Led · Equity · Nov 2021

  One Health Group develops Voyce, a noncontact intelligent biometric sensor and patented mobile health assessment technology for remote animal health diagnostics. Voyce provides real-time monitoring of vitals and conditions including heart rate, heart function, blood pressure, pulmonary irregularities, tumor detection, cardiopulmonary monitoring and sleep apnea at clinically proven accuracies. The device is non-invasive and can be housed on a collar as a small unobtrusive unit; earlier versions have been used globally in clinics and major research facilities, amassing over a million hours of clinic time. One Health Group partners with academic institutions and medical-technology companies to advance its biometric monitoring platform. The company aims to integrate animal, human, and environmental data to improve diagnostics, monitoring, and preventive care. Voyce version 4, with substantial technological updates, is slated for release in 2023.

• Paradromics

  Participated · Seed · Jul 2021

  Paradromics is building the Connexus Brain-Computer Interface, an array of tiny electrodes implanted directly into brain tissue that reads neural signals and converts them into useful outputs, with an initial focus on restoring communication for people with severe paralysis. The company earned the FDA’s Breakthrough Device designation in 2023 and is preparing to launch its first human clinical trial later this year after opening an official patient registry in July. Although its technology has not yet received full FDA approval, Paradromics aims to commercialize BCI-based therapies before the end of the decade. The startup positions itself alongside competitors such as Neuralink, Precision Neuroscience, and Synchron, none of which have final FDA clearance. As part of its growth strategy, Paradromics will establish a Brain-Computer Interface Center of Excellence in Neom, Saudi Arabia. The company has not publicly disclosed revenue, user numbers, or other operating metrics. Its continued progress depends on securing regulatory approvals and scaling manufacturing for its high-channel neural implants.

• Leo Cancer Care

  Participated · Series B · Jul 2021

  Leo Cancer Care develops an integrated upright platform that applies the same seating-based architecture across imaging, photon therapy and proton therapy. Its upright imaging system is FDA-cleared and is used for treatment planning and has planned future radiology applications. On the treatment side, its Marie® platform enables a compact upright proton therapy room by fixing the beam and rotating a seated patient, a design that Stanford Medicine used to deliver the world’s first compact upright proton treatment on June 4, 2026. The company reports adoption by leading centers including Stanford Medicine, Dana-Farber Cancer Institute and McLaren Health Care and says its approach can enable installations in existing radiotherapy vaults. Leo plans to use the $65M Series D to scale manufacturing, accelerate commercial deployment globally, and continue clinical and product development across its proton, photon and imaging offerings.

• Aevice Health

  Participated · Series A · Jun 2021

  Aevice Health is a Singapore-based medical technology company. Regulatory filings indicate the company has secured $7 million in a seed-plus (seed extension) funding round. The published report does not provide details about the company's specific products, services, or operating metrics. No investor names, previous rounds, valuation, or use of proceeds were disclosed in the article. The fundraising information is cited from regulatory filings reported by the publication. Aevice Health is a Singapore-based provider of remote respiratory monitoring solutions built around its flagship device, the AeviceMD. The AeviceMD is FDA-cleared and HSA-approved for remote respiratory monitoring. On 15 May 2024 the company announced a US$1.0 million investment from A&D Company to accelerate digital health initiatives. The funding is intended to support extension of AeviceMD into the US and Japan markets and further product deployment. The collaboration gives Aevice access to A&D Company's medical-technology expertise and network while allowing A&D to leverage Aevice's technology to create new healthcare solutions. JETRO Singapore fostered the partnership; the LinkedIn announcement named Adrian Ang, Rex X. Tan and the team. Aevice Health is a Singapore-based medical technology spin-off from Nanyang Technological University that develops non-invasive wearable devices for early detection of cardiopulmonary illnesses. Its flagship product, AeviceMD, is an AI-powered wearable stethoscope placed on the chest to continuously listen in real time and detect cardiopulmonary abnormalities such as wheezing. The company raised S$2.8 million (US$2.1 million) in a pre-Series A round participated by Toho Holdings, Pureland Group Venture, Silicon Solutions Partners, AIP Ventures and SEEDS Capital. Proceeds will be used to further develop its proprietary technology and expand its remote respiratory monitoring solution into Japan to augment the country’s telehealth landscape. Aevice Health has entered a strategic partnership with Tokyo-listed Toho Holdings to develop and market AeviceMD in Japan, and last year signed a partnership with The Health Bank Global to expand into the Middle East, North Africa and South Asia. The company aims to advance remote patient monitoring and enable continuous, remote self-management of chronic respiratory diseases for hospitals, insurers, pharmaceutical companies and health systems.

No current team members are available.